March 16, 2016/Cancer

When Screening for Gynecologic Cancer Isn’t Enough

How to ensure your patients receive appropriate care

16-CCR-337-Gyn-Cancer-Screening-CQD-Image

Pap tests and human papillomavirus (HPV) tests are so effective at screening for cervical cancer that mortality from the disease has decreased significantly in the past 30 years. Unfortunately, there are no effective screening tools for other types of gynecologic cancers, says Haider Mahdi, MD, MPH, a gynecologic oncologist at Cleveland Clinic. That’s why watching for symptoms is essential for detecting:

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ovarian cancer. “Most women are diagnosed with late-stage disease because warning signs are nonspecific and often over­looked,” says Dr. Mahdi. Indicators include:

  • Low appetite
  • Digestion problems
  • Unintentional weight loss
  • Abdominal distension
  • Constipation
  • Bladder problems

Endometrial cancer. Postmenopausal bleeding is the most common symptom. Fortunately, bleeding usually occurs in the disease’s early stage, making early diagnosis and cure more feasible.

Vulvar or vaginal cancers. A vulvar mass, vulvar itching or vaginal bleeding are the most common symptoms.

Advertisement

On the front lines

Primary care physicians and Ob/Gyn providers are on the front lines in gynecologic cancer detection. According to Dr. Mahdi, their important role is fourfold:

  1. Ensure patients comply with screening guidelines for cervical cancer. Guidelines changed in 2012,” says Dr. Mahdi. “Inform women age 30 and older that cotesting with a Pap test and HPV test once every five years is preferred to having a Pap test alone every three years for detecting cervical cancer or precancer.”
  2. Educate patients on warning signs. Especially for ovarian, endometrial, vulvar and vaginal cancers, patients should know to watch for the symptoms already listed.
  3. Identify patients at high risk. Women with a family history of gynecologic cancer, or a personal or family history of breast, pancreatic, colon or other cancers (particularly those with BRCA1 or BRCA2 mutations or Lynch syndrome) are at higher risk. Other risk factors vary by cancer type but include:
  • More menstrual cycles over a lifetime (e.g., early menarche, late menopause, never being pregnant)
  • History of breast cancer
  • Taking certain fertility drugs
  • Estrogen therapy
  • Obesity
  • Diabetes
  1. Refer patients quickly. “Even if you’re unsure — refer,” says Dr. Mahdi. “Early referrals may give patients more treatment options, such as primary surgery instead of primary chemotherapy, or laparoscopic surgery instead of open surgery. Options are more limited with metastatic disease.”

Finding advanced treatment options

Dr. Mahdi says that patients diagnosed with gynecological cancers should be referred to treatment centers with advanced capabilities such as:

  • Single-incision laparoscopic and robotic surgeries
  • Intraperitoneal chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Investigational treatments offered through membership in NRG Oncology, an international research alliance
  • Targeted therapy, based on genomic tumor testing
  • Genetic testing for hereditary cancers

Related Articles

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

viral-induced cancer
April 3, 2024/Cancer
Mechanism of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) May Serve as Clue to More Effective Treatment

Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Cleveland Clinic physiatrist
March 22, 2024/Cancer/Innovations
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Ad